GuideInfectious diseases
Vancomycin dosing and kidney function with cystatin C
Sheet on vancomycin dosing guided by creatinine-cystatin C eGFR (Frazee, 2017) and the current recommendation to dose by AUC.
Updated 3 November 2026
When to use it
Adults receiving intravenous vancomycin, especially critically ill patients or those with abnormal muscle mass, in whom creatinine alone poorly estimates kidney function.
Warning
The original protocol (2017) was based on trough targets, now replaced by AUC-guided dosing (2020 consensus guideline). Follow your institution's pharmacokinetic protocol.
The Frazee study (2017)
Quality improvement project in three Mayo Clinic ICUs. A dosing algorithm based on creatinine-cystatin C eGFR (CKD-EPI) was compared with the previous one based on Cockcroft-Gault creatinine clearance. With the new algorithm, 50% of patients reached the target trough versus 28% (adjusted OR 2.79), with no difference in clinical outcomes. It was non-randomised and in patients with stable kidney function.
Keep reading in the app
- Why it is not calculated here
- Current recommendation (ASHP/IDSA/PIDS/SIDP, 2020)
- Role of cystatin C
Practical tip
Cystatin C depends little on muscle mass: it is useful in amputees and in malnourished, sarcopenic or long-term bedridden patients.
2 more practical tips in the app.
Reference
- Frazee E, Rule AD, Lieske JC, et al. Cystatin C-guided vancomycin dosing in critically ill patients: a quality improvement project. Am J Kidney Dis. 2017;69(5):658-666.
- Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835-864.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
